Literature DB >> 447949

Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics.

R W Weber, M Hoffman, D A Raine, H S Nelson.   

Abstract

Forty-five patients with moderately severe perennial bronchial asthma were challenged by ingestion of: acetylsalicyclic acid (ASA); 4 azo dyes (tartrazine, sunset yellow, amaranth, and ponceau); 3 non-azo dyes (erythrosine, brilliant blue, and indigotin); sodium benzoate (NaB); parahydroxybenzoic acid (OHBA); butylated hydroxyanisole (BHA); and butylated hydroxytoluene (BHT). A fall in forced expiratory volume is one second (FEV1) greater than 25% from baseline was considered positive. Seven patients who gave an unequivocal history of aspirin intolerance were not challenged with ASA; an additional 13 had positive open challenges to ASA, giving an apparent incidence of aspirin sensitivity of 20/45. The presence of nasal polyps, simusitis, or the regular use of corticosteroids, either singly or in combination, was not associated with an increased incidence of reactions to ASA. Significant bronchoconstriction to open challenges with agents other than ASA was less frequent. Positive open challenges to all substances except aspirin were followed by double-blind challenges which were positive in only 3 instances: 1 each with erythrosine, ponceau, and NaB/OHBA. Our findings confirm that ASA intolerance is relatively common but suggest on the other hand that reactions to dyes and preservatives are uncommon cause of clinically significant bronchoconstriction in moderately severe perennial asthmatics.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 447949     DOI: 10.1016/0091-6749(79)90080-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  31 in total

1.  Pitfalls of 'inert' ingredients.

Authors:  J S Millar
Journal:  Br J Gen Pract       Date:  2001-07       Impact factor: 5.386

2.  The aspirin disease.

Authors:  D Schiavino; E Nucera; A Milani; M Del Ninno; A Buonomo; J Sun; G Patriarca
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 3.  Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).

Authors:  Ronald A Simon; Kristen M Dazy; Jeremy D Waldram
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

4.  Allergy-epitomes of progress: asthmogenic drugs.

Authors:  T Forster; S M Nagy
Journal:  West J Med       Date:  1981-07

Review 5.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

Review 6.  Drug allergy: an overview.

Authors:  R D DeSwarte
Journal:  Clin Rev Allergy       Date:  1986-05

Review 7.  Tartrazine exclusion for allergic asthma.

Authors:  K D Ardern; F S Ram
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 8.  Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice.

Authors:  Christine Jenkins; John Costello; Linda Hodge
Journal:  BMJ       Date:  2004-02-21

9.  Commentary: acetylsalicylic acid or aspirin?

Authors:  J F Crocker
Journal:  Can Med Assoc J       Date:  1982-03-15       Impact factor: 8.262

Review 10.  Analgesics, allergy and asthma.

Authors:  A Szczeklik
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.